| | |
| | |
| Clinical data | |
|---|---|
| Other names | 2C-D-5-EtO; 2CD-5-EtO; 5-Ethoxy-2-methoxy-4-methylphenethylamine; 2-Methoxy-5-ethoxy-4-methylphenethylamine; 4-Methyl-2-methoxy-5-ethoxyphenethylamine; 2-Methoxy-4-methyl-5-ethoxyphenethylamine |
| Routes of administration | Oral [1] |
| Drug class | Serotonergic psychedelic; Hallucinogen |
| Pharmacokinetic data | |
| Onset of action | ~2 hours (peak) [1] |
| Duration of action | 12 hours [1] [2] [3] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C12H19NO2 |
| Molar mass | 209.289 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| | |
2CD-5EtO, also known as 5-ethoxy-2-methoxy-4-methylphenethylamine, is a psychedelic drug of the phenethylamine, 2C, and TWEETIO families related to 2C-D. [1] [2] [3] It is the analogue of 2C-D in which the methoxy group at the 5 position has been extended to an ethoxy group. [1] [2] [3]
In his book PiHKAL (Phenethylamines I Have Known and Loved) and other publications, Alexander Shulgin lists 2CD-5EtO's dose as 40 to 50 mg orally, its onset as slow and gradual, its time to peak or full effects as about 2 hours, and its duration as 12 hours. [1] [2] [3] The effects of 2CD-5EtO were said to include being "largely free from excitement", having "a friendly openness and outgoingness that allowed easy talk, interaction, humor", and allowing for healthy appetite. [1]
The chemical synthesis of 2CD-5EtO has been described. [1]
2CD-5EtO was first described in the literature by Alexander Shulgin in his book PiHKAL (Phenethylamines I Have Known and Loved) in 1991. [1] It was developed and tested by Darrell Lemaire, with publication via personal communication with Shulgin. [2] [4] [5] [6] [7]
2CD-5EtO is a controlled substance in Canada under phenethylamine blanket-ban language. [8]